Johnson & Johnson’s Nipocalimab Shows Strong SLE Results
LONDON, United Kingdom, June 3, 2026 Johnson & Johnson has announced positive late-breaking results from its Phase 2 JASMINE...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON, United Kingdom, June 3, 2026 Johnson & Johnson has announced positive late-breaking results from its Phase 2 JASMINE...
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 IDEAYA Biosciences and Roche have entered into a strategic clinical collaboration...
SHANGHAI, China, June 3, 2026 Antengene has announced the first preclinical data for ATG-207, its investigational αCD3-TGF-β bifunctional fusion...
